GW最後の日曜日は雨だった。雨、急な気温変化、低気圧に体が弱いようで、一日重く感じた。月曜日は午後から雨が上がって穏やかな天気。気持ちも少し回復してきている気がする。
"
[HTML] A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
with IPF. These real-world data were consistent with the safety profile observed in clinical …
-
A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis:
Abstract
Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases. Placebo-controlled trials showed that the adverse event profile of nintedanib was characterised mainly by gastrointestinal events, particularly diarrhoea. We review the data from all published real-world studies of the safety of nintedanib in patients with IPF. These real-world data were consistent with the safety profile observed in clinical trials and described in the product label. The most common adverse events were diarrhoea, nausea and vomiting, but these infrequently led to permanent treatment discontinuation. Liver enzyme elevations were observed, supporting the recommendation for regular monitoring of liver enzymes, particularly in the first few months of treatment. Bleeding and cardiovascular adverse events were rarely reported. As in clinical trials, in real-world studies, reductions of the nintedanib dose, treatment interruptions and use of anti-diarrhoeal medications were frequently employed to manage adverse events. Few data are available on the use of nintedanib in patients who are elderly or have advanced disease, but there are some data to suggest a greater rate of treatment discontinuation in these patients. Effective management of adverse events associated with nintedanib is important to minimise their impact. - 特発性肺線維症患者におけるニンテダニブの安全性に関するリアルワールドデータのナラティブレビュー:
概要 - ニンテダニブ: チロシンキナーゼ阻害剤、IPFおよび他の進行性線維性間質性肺疾患治療薬
- 有害事象プロファイル: 主に消化器系、特に下痢
- 現実世界の研究: 安全性プロファイル一致、最も一般的な有害事象は下痢、吐き気、嘔吐
- 肝酵素上昇: 治療初期、定期的なモニタリング推奨
- 出血・心血管系有害事象: めったに報告されず
- 有害事象管理: ニンテダニブ投与量削減、治療中断、下痢止め薬使用
- 高齢者・進行疾患患者: ニンテダニブ使用データ少ない、治療中止率高い可能性
- 有害事象効果的管理: 影響最小限に抑えるため重要
"
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
癒しの音楽をお届けいたします。
###
